Brought to you by 
Pfizer and Reprogenesis develop tissue-eng'd urology products
13 Jul 1999
Executive Summary
Pfizer Inc.'s American Medical Systems division and Reprogenesis entered into an agreement to develop products for urology based on the tissue engineering technology of Reprogenesis.
Deal Industry
- Biotechnology
- Medical Devices
-
Medical Devices
- Biomaterials
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer and Reprogenesis develop tissue-eng'd urology products
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice